European Journal of Molecular & Clinical Medicine

Number of non-alcoholic fatty liver disease (NAFLD) cases is increasing over time due to alteration of food habit, increase incidence of metabolic syndrome, and lack of exercise. Liver biopsy is the test for diagnosis and staging of NAFLD, but nowadays several biochemical markers, scoring systems, and imaging studies are available to diagnose and stage NAFLD which is linked to end-stage liver disease, hepatocellular cancer, and elevated cardiovascular- and cancer-related morbidity and mortality. Therefore urgent diagnosis and management are required to avoid complications related to NAFLD. This study summarizes the latest evidence on the epidemiology, natural history, pathogenesis, diagnosis and management of NAFLD.

NAFLD is a spectrum of liver lesions ranging from simple hepatic steatosis to NASH with progressive fibrosis leading to cirrhosis and liver failure in some patients and eventually hepatocellular carcinoma. The different parts of this spectrum are probably best regarded as parts of a histological continuum. All patients underwent ultrasound (USG) of the abdomen to detect fatty changes in the liver, performed by aexperienced radiologist, using a high-resolution B-mode ultrasonography system, having an electric linear transducer mid frequency of 3-5 MHz.The scanning was done for an average of 20 minutes.
In our study out of 50 patients,22(44%) patients were having diabetic neuropathy on the basis of clinical examination,out of them 10 (45.45%) patients were males & 12 (54.54%) patients were females. There was higher prevalence of diabetic neuropathy in female patients. 28 (56%) patients were negative for neuropathy. Out of total 50 diabetic patients with NAFLD, 31 (62%) patients were having evidence of CAD, out of 31 patients, 17 (54.8%) were male & 14 (45.2%) were female. 19 (38%) patients having no evidence of CAD.

Number of non-alcoholic fatty liver disease (NAFLD) cases is increasing over time due to alteration of food habit, increase incidence of metabolic syndrome, and lack of exercise. Liver biopsy is the test for diagnosis and staging of NAFLD, but nowadays several biochemical markers, scoring systems, and imaging studies are available to diagnose and stage NAFLD which is linked to end-stage liver disease, hepatocellular cancer, and elevated cardiovascular- and cancer-related morbidity and mortality. Therefore urgent diagnosis and management are required to avoid complications related to NAFLD. This study summarizes the latest evidence on the epidemiology, natural history, pathogenesis, diagnosis and management of NAFLD.